Distribution And Therapeutic Outcomes Of Intergenic Sequence-Alk Fusion And Coexisting Alk Fusions In Lung Adenocarcinoma Patients

C. Cai,Y. Tang,Y. Li,Y. Chen,P. Tian,Y. Wang,Y. Gong,F. Peng,Y. Zhang,M. Yu,K. Wang,J. Zhu,Y. Lu,M. Huang

Lung Cancer（2021）

引用 8|浏览22

暂无评分

摘要

•Non-negligible incidences of intergenic sequence–ALK, non-EML4-ALK and coexisting of multi-fusions.•Higher occurrence rates of intergenic sequence–ALK and non-EML4-ALK in patients with multi-fusions.•Intergenic-sequence ALK fusion is a potential therapeutic target for ALK inhibitors.•Neither rearrangement number and type have the significant effect on the therapeutic outcome.

查看译文

关键词

genomic profiling, clinical outcome, ALK rearrangement

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要